[go: up one dir, main page]

MA56508B1 - Inhibiteur de l'egfr pour le traitement du cancer - Google Patents

Inhibiteur de l'egfr pour le traitement du cancer

Info

Publication number
MA56508B1
MA56508B1 MA56508A MA56508A MA56508B1 MA 56508 B1 MA56508 B1 MA 56508B1 MA 56508 A MA56508 A MA 56508A MA 56508 A MA56508 A MA 56508A MA 56508 B1 MA56508 B1 MA 56508B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
egfr inhibitor
formula
cancer
ring
Prior art date
Application number
MA56508A
Other languages
English (en)
Other versions
MA56508A (fr
Inventor
Bernd Kuhn
Daniel Rueher
Georg Jaeschke
Antonio Ricci
Cosimo Dolente
Sander Ulrike Obst
Sandra Steiner
Annick Goergler
David Hewings
Yvonne Nagel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA56508A publication Critical patent/MA56508A/fr
Publication of MA56508B1 publication Critical patent/MA56508B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de formule (i) contenant un cycle thiazole, un cycle indazole et un système cyclique 6,7-dihydro-5h-pyrrolo[l,2- c]imidazole, des compositions pharmaceutiques le contenant et son utilisation médicale. Les composés sont décrits en tant qu'inhibiteurs allostériques sélectifs de t790m/l858r, t790m/l858r/c797s, l858r, l858r/c797s contenant des mutants egfr et sont donc utiles pour le traitement du cancer, en particulier du cancer du poumon non à petites cellules. (formule i)
MA56508A 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer MA56508B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (fr) 2019-06-21 2020-06-19 Inhibiteur d'egfr pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA56508A MA56508A (fr) 2022-04-27
MA56508B1 true MA56508B1 (fr) 2023-11-30

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56508A MA56508B1 (fr) 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer

Country Status (29)

Country Link
US (4) US20220315593A1 (fr)
EP (4) EP3986895B1 (fr)
JP (4) JP7550799B2 (fr)
KR (1) KR20220024105A (fr)
CN (4) CN113993873B (fr)
AR (4) AR119208A1 (fr)
AU (1) AU2020295703A1 (fr)
BR (1) BR112021025445B1 (fr)
CA (1) CA3140485A1 (fr)
CL (1) CL2021003408A1 (fr)
CO (1) CO2021017173A2 (fr)
CR (1) CR20210624A (fr)
DK (1) DK3986897T3 (fr)
ES (1) ES2961187T3 (fr)
FI (1) FI3986897T3 (fr)
HR (1) HRP20231276T1 (fr)
HU (1) HUE063676T2 (fr)
IL (1) IL288522B2 (fr)
LT (1) LT3986897T (fr)
MA (1) MA56508B1 (fr)
MX (1) MX2021015464A (fr)
PE (1) PE20220576A1 (fr)
PH (1) PH12021553190A1 (fr)
PL (1) PL3986897T3 (fr)
PT (1) PT3986897T (fr)
RS (1) RS64720B1 (fr)
SI (1) SI3986897T1 (fr)
TW (3) TW202115072A (fr)
WO (4) WO2020254562A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210624A (es) 2019-06-21 2022-02-14 Hoffmann La Roche Inhibidor de egfr para el tratamiento de cáncer
PH12021553018A1 (en) 2019-06-21 2023-08-23 Hoffmann La Roche New egfr inhibitors
EP4522617A1 (fr) * 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Nouveaux dérivés d'indazole
CN119173253A (zh) * 2022-05-13 2024-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的变构和正构egfr抑制剂的组合产品
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
WO2009158369A1 (fr) 2008-06-25 2009-12-30 Schering Corporation Synthèse et utilisation d’agents antibactériens hétérocycliques
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2015095807A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitements du cancer au moyen de combinaisons d'inhibiteurs de l'egfr et de l'erk
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016077375A1 (fr) * 2014-11-10 2016-05-19 Genentech, Inc. Inhibiteurs de bromodomaines et leurs utilisations
EP3294705B1 (fr) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Inhibiteurs d'ebna1 et méthodes les utilisant
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (fr) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Composés
WO2019046668A1 (fr) * 2017-08-31 2019-03-07 Kezar Life Sciences Thiazoles à substitution amide utilisés en tant qu'inhibiteurs de la sécrétine protéique
AU2019294414B2 (en) 2018-06-29 2023-06-29 F. Hoffmann-La Roche Ag Compounds
WO2020254544A1 (fr) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Nouveaux inhibiteurs d'egfr
CR20210624A (es) 2019-06-21 2022-02-14 Hoffmann La Roche Inhibidor de egfr para el tratamiento de cáncer
PH12021553018A1 (en) 2019-06-21 2023-08-23 Hoffmann La Roche New egfr inhibitors

Also Published As

Publication number Publication date
JP2022537191A (ja) 2022-08-24
DK3986897T3 (da) 2023-10-30
IL288522B1 (en) 2024-10-01
AR119209A1 (es) 2021-12-01
CN113993872A (zh) 2022-01-28
WO2020254568A1 (fr) 2020-12-24
JP7550798B2 (ja) 2024-09-13
CO2021017173A2 (es) 2022-01-17
EP3986895A1 (fr) 2022-04-27
CR20210624A (es) 2022-02-14
JP7550799B2 (ja) 2024-09-13
IL288522B2 (en) 2025-02-01
JP7530391B2 (ja) 2024-08-07
PH12021553190A1 (en) 2022-11-07
SI3986897T1 (sl) 2023-12-29
TW202115074A (zh) 2021-04-16
CN114008049B (zh) 2024-07-05
CL2021003408A1 (es) 2022-10-14
AU2020295703A1 (en) 2022-01-06
AR119206A1 (es) 2021-12-01
EP3986898B1 (fr) 2023-03-15
EP3986897A1 (fr) 2022-04-27
AR119210A1 (es) 2021-12-01
KR20220024105A (ko) 2022-03-03
BR112021025445B1 (pt) 2024-02-27
EP3986896B1 (fr) 2023-03-15
CN113993872B (zh) 2024-09-24
US20220135571A1 (en) 2022-05-05
FI3986897T3 (fi) 2023-10-20
EP3986896A1 (fr) 2022-04-27
MA56508A (fr) 2022-04-27
AR119208A1 (es) 2021-12-01
JP2022538403A (ja) 2022-09-02
WO2020254572A1 (fr) 2020-12-24
TW202115053A (zh) 2021-04-16
EP3986898A1 (fr) 2022-04-27
JP7550800B2 (ja) 2024-09-13
CN113966335A (zh) 2022-01-21
HRP20231276T1 (hr) 2024-02-02
CN113966335B (zh) 2024-08-02
MX2021015464A (es) 2022-01-24
JP2022538055A (ja) 2022-08-31
US20220315593A1 (en) 2022-10-06
IL288522A (en) 2022-01-01
WO2020254562A1 (fr) 2020-12-24
WO2020254565A1 (fr) 2020-12-24
JP2022537769A (ja) 2022-08-29
US20220315592A1 (en) 2022-10-06
ES2961187T3 (es) 2024-03-08
RS64720B1 (sr) 2023-11-30
PL3986897T3 (pl) 2024-01-22
PE20220576A1 (es) 2022-04-20
EP3986895B1 (fr) 2023-03-15
BR112021025445A2 (pt) 2022-02-01
EP3986897B1 (fr) 2023-08-30
TW202115071A (zh) 2021-04-16
TW202115072A (zh) 2021-04-16
CN114008049A (zh) 2022-02-01
HUE063676T2 (hu) 2024-01-28
US20230054473A1 (en) 2023-02-23
CN113993873B (zh) 2024-08-02
CA3140485A1 (fr) 2020-12-24
PT3986897T (pt) 2023-10-23
LT3986897T (lt) 2023-11-10
CN113993873A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
MA56508B1 (fr) Inhibiteur de l'egfr pour le traitement du cancer
MX2022008066A (es) Compuestos triciclicos sustituidos.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12022551014A1 (en) Substituted tricyclic compounds
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MA34342B1 (fr) Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA31419B1 (fr) Derives de pyridine
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2020010805A (es) Inhibidores de bcl6.
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
AR115663A1 (es) Compuestos
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
ZA202104940B (en) Novel substituted sulfonylurea derivatives
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
MX2024002409A (es) Terapias contra el cancer.
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.